Claire Thomas - GlaxoSmithKline PLC Senior Vice President - Human Resources
| GSK Stock | USD 39.27 0.33 0.83% |
President
Ms. Claire Thomas is Senior Vice President Human Resources of GlaxoSmithKline PLC., since May 2008. Claire was appointed to the CET as Senior Vice President, Human Resources in 2008. She joined the Company in 1996 as Senior Manager, Human Resources, Sales and Marketing Group, UK Pharmaceuticals before becoming Director of Human Resources for UK Pharmaceuticals in 1997. She was appointed Senior Vice President, Human Resources, Pharmaceuticals Europe in 2001, and Senior Vice President, Human Resources, Pharmaceuticals International in 2006. Prior to GSK, Claire worked for the Ford Motor Company, holding various positions in Human Resources. She has a BS degree in Economics, Management and Industrial Relations from the University of Wales. since 2008.
| Tenure | 16 years |
| Address | 980 Great West Road, Brentford, United Kingdom, TW8 9GS |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline PLC Management Efficiency
The company has Return on Asset of 0.0881 % which means that on every $100 spent on assets, it made $0.0881 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4638 %, implying that it generated $0.4638 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.18. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Robert Crudup | SEI Investments | 69 | |
| Michael Peterson | SEI Investments | 56 | |
| Ryan Hicke | SEI Investments | 45 | |
| Jeffrey Klauder | SEI Investments | 64 | |
| Paul Klauder | SEI Investments | 50 | |
Management Performance
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.0881 |
GlaxoSmithKline PLC ADR Leadership Team
Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vindi Banga, Senior Independent Non-Executive Director | ||
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Daniel Podolsky, Non-Executive Independent Director | ||
| Harry Dietz, Non-Executive Independent Director, Scientific and Medical Expert | ||
| Emma Walmsley, Chief Executive Officer, Executive Director | ||
| Luc Debruyne, President - Global Vaccines | ||
| Andrew Witty, CEO, Executive Director | ||
| CA BSc, President Development | ||
| Philip Thomson, President Affairs | ||
| Roy Anderson, Non-Executive Independent Director | ||
| Bill Louv, Senior Vice President - Core Business Services | ||
| Abbas Hussain, President Global Pharmaceuticals | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Hans Wijers, Independent Non-Executive Director | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Deryck Maughan, Senior Independent Non-Executive Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, Senior Vice President - Global Communications and CEO Office | ||
| James Ford, Senior Vice President, Group General Counsel, Legal and Compliance | ||
| Daniel Troy, Sr. VP and General Counsel | ||
| Shah Hussain, President - Europe, Japan & EMAP | ||
| Manvinder Banga, Non-Executive Director | ||
| David Redfern, Chief Strategy Officer | ||
| Patrick Vallance, President - Pharmaceuticals R&D | ||
| Stacey Cartwright, Non-Executive Independent Director | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare | ||
| Claire Thomas, Senior Vice President - Human Resources | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director | ||
| Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare | ||
| Charles Bancroft, Non-Executive Independent Director | ||
| Philip Hampton, Independent Non-Executive Director | ||
| Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director | ||
| Diana Conrad, Senior Vice President - Human Resources | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Shobie Ramakrishnan, Chief Digital and Technology Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Stephanie Burns, Non-Executive Independent Director | ||
| Julie Brown, Chief Officer | ||
| Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Anne Beal, Non-Executive Independent Director | ||
| Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert | ||
| Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert | ||
| Victoria Whyte, Company Secretary | ||
| Tony Wood, Chief Scientific Officer - Designate | ||
| Jonathan Symonds, Independent Non-Executive Chairman of the Board | ||
| Iain Mackay, Chief Financial Officer, Executive Director | ||
| Karenann Terrell, Chief Digital and Technology Officer |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.0881 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 173.83 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Institutions | 14.40 % | ||||
| Number Of Shares Shorted | 4.83 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 4.96 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 0.58 | Earnings Share 2.99 | Revenue Per Share 14.97 | Quarterly Revenue Growth 0.092 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.